이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

천식을 앓고 있는 12세 이상 참가자에게 추진제 HFA-152a 또는 HFA-134a가 포함된 MDI를 통해 살부타몰을 투여한 3개월 치료의 안전성과 내약성을 평가하고 비교하기 위한 연구

2026년 9월 11일 업데이트: GlaxoSmithKline

추진제 HFA-152a 또는 참조 HFA-134a가 포함된 정량 흡입기를 통해 투여될 때 Salbutamol 구조 약물의 장기 안전성을 평가하기 위한 무작위 이중 맹검 병렬 그룹 다기관 연구

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma

연구 개요

연구 유형

중재적

등록 (실제)

471

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 15669
        • GSK Investigational Site
      • Larissa, 그리스, 41110
        • GSK Investigational Site
      • Thessaloniki, 그리스, 57010
        • GSK Investigational Site
    • California
      • North Hollywood, California, 미국, 91606-3287
        • GSK Investigational Site
      • San Mateo, California, 미국, 94403
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, 미국, 33180
        • GSK Investigational Site
      • Clearwater, Florida, 미국, 33756
        • GSK Investigational Site
      • DeLand, Florida, 미국, 32720
        • GSK Investigational Site
      • Miami, Florida, 미국, 33173
        • GSK Investigational Site
      • Miami, Florida, 미국, 33144
        • GSK Investigational Site
      • Miami, Florida, 미국, 33155
        • GSK Investigational Site
      • Naples, Florida, 미국, 34102
        • GSK Investigational Site
      • Plantation, Florida, 미국, 33317
        • GSK Investigational Site
      • Winter Park, Florida, 미국, 32789-3385
        • GSK Investigational Site
    • Georgia
      • Rincon, Georgia, 미국, 31326-5131
        • GSK Investigational Site
      • Stonecrest, Georgia, 미국, 30038
        • GSK Investigational Site
    • Kentucky
      • Louisville, Kentucky, 미국, 40217
        • GSK Investigational Site
      • Owensboro, Kentucky, 미국, 42301
        • GSK Investigational Site
    • Massachusetts
      • Fall River, Massachusetts, 미국, 02723-1511
        • GSK Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55402-2508
        • GSK Investigational Site
      • Minneota, Minnesota, 미국, 56001
        • GSK Investigational Site
    • Mississippi
      • Olive Branch, Mississippi, 미국, 38654
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, 미국, 65203
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, 미국, 89052-5015
        • GSK Investigational Site
    • New Jersey
      • Jersey City, New Jersey, 미국, 07306
        • GSK Investigational Site
      • Riverdale, New Jersey, 미국, 07457
        • GSK Investigational Site
    • New York
      • Brooklyn, New York, 미국, 11220
        • GSK Investigational Site
    • North Carolina
      • Asheville, North Carolina, 미국, 28803
        • GSK Investigational Site
      • Winston-Salem, North Carolina, 미국, 27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, 미국, 45231
        • GSK Investigational Site
      • Dublin, Ohio, 미국, 43016
        • GSK Investigational Site
    • Oregon
      • Medford, Oregon, 미국, 97504
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, 미국, 15241
        • GSK Investigational Site
      • Pottstown, Pennsylvania, 미국, 19464-3241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill, South Carolina, 미국, 29732
        • GSK Investigational Site
      • Spartanburg, South Carolina, 미국, 29303
        • GSK Investigational Site
      • Spartanburg, South Carolina, 미국, 29303-4225
        • GSK Investigational Site
      • Union, South Carolina, 미국, 29379-7409
        • GSK Investigational Site
    • Texas
      • Sugar Land, Texas, 미국, 77479
        • GSK Investigational Site
      • Tomball, Texas, 미국, 77375-3332
        • GSK Investigational Site
      • Barcelona, 스페인, 08017
        • GSK Investigational Site
      • Barcelona, 스페인, 08540
        • GSK Investigational Site
      • Benalmádena, 스페인, 29631
        • GSK Investigational Site
      • Madrid, 스페인, 28041
        • GSK Investigational Site
      • Madrid, 스페인, 28040
        • GSK Investigational Site
      • Madrid, 스페인, 28031
        • GSK Investigational Site
      • Marbella, 스페인, 29603
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, 스페인, 28223
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1425BEN
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1426ABP
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1425AZE
        • GSK Investigational Site
      • La Plata, 아르헨티나, 1900
        • GSK Investigational Site
      • Mendoza, 아르헨티나, M5500CCG
        • GSK Investigational Site
      • Bebington, 영국, CH63 9JP
        • GSK Investigational Site
      • Cambridgeshire, 영국, CB7 5JD
        • GSK Investigational Site
      • Corby, 영국, NN17 2UR
        • GSK Investigational Site
      • Greater Manchester, 영국, OL6 6HD
        • GSK Investigational Site
      • Guisborough, 영국, TS14 7DJ
        • GSK Investigational Site
      • Hounslow, 영국, TW3 3EL
        • GSK Investigational Site
      • Rhyl, 영국, LL18 4HZ
        • GSK Investigational Site
      • Uttoxeter, 영국, ST14 5JX
        • GSK Investigational Site
      • Cagliari, 이탈리아, 09042
        • GSK Investigational Site
      • Florence, 이탈리아, 50134
        • GSK Investigational Site
      • Foggia, 이탈리아, 71100
        • GSK Investigational Site
      • Milan, 이탈리아, 20162
        • GSK Investigational Site
      • Naples, 이탈리아, 80131
        • GSK Investigational Site
      • Padova, 이탈리아, 35128
        • GSK Investigational Site
      • Torino, 이탈리아, 10128
        • GSK Investigational Site
      • Tradate VA, 이탈리아, 21100
        • GSK Investigational Site
      • Verona, 이탈리아, 37134
        • GSK Investigational Site
    • RM
      • Roma, RM, 이탈리아, 00161
        • GSK Investigational Site
    • Ontario
      • Ajax, Ontario, 캐나다, L1S 2J5
        • GSK Investigational Site
      • Brampton, Ontario, 캐나다, L6T 0G1
        • GSK Investigational Site
      • Ottawa, Ontario, 캐나다, K1H 1E4
        • GSK Investigational Site
      • Toronto, Ontario, 캐나다, M9V 4B4
        • GSK Investigational Site
      • Windsor, Ontario, 캐나다, N8X 2G1
        • GSK Investigational Site
    • Quebec
      • Québec, Quebec, 캐나다, G1V 4W2
        • GSK Investigational Site
      • Québec, Quebec, 캐나다, G1W 4R4
        • GSK Investigational Site
      • Pathum Thani, 태국, 12120
        • GSK Investigational Site
      • Panama City, 파나마
        • GSK Investigational Site
      • Panama City, 파나마, 7099
        • GSK Investigational Site
      • Panama City, 파나마, 7002
        • GSK Investigational Site
      • Bialystok, 폴란드, 15-010
        • GSK Investigational Site
      • Bielsko-Biala, 폴란드, 43-300
        • GSK Investigational Site
      • Chorzów, 폴란드, 41-500
        • GSK Investigational Site
      • Elblag, 폴란드, 82-300
        • GSK Investigational Site
      • Katowice, 폴란드, 40-600
        • GSK Investigational Site
      • Ostrowiec Świętokrzyski, 폴란드, 27-400
        • GSK Investigational Site
      • Płock, 폴란드, 09-407
        • GSK Investigational Site
      • Tarnów, 폴란드, 33-100
        • GSK Investigational Site
      • Amiens, 프랑스, 80054
        • GSK Investigational Site
      • Argenteuil, 프랑스, 95100
        • GSK Investigational Site
      • Créteil, 프랑스, 94010
        • GSK Investigational Site
      • Poitiers, 프랑스, 86021
        • GSK Investigational Site
      • Pontoise, 프랑스, 95303
        • GSK Investigational Site
      • Strasbourg, 프랑스, 67091
        • GSK Investigational Site
      • Iloilo City, 필리핀 제도, 5000
        • GSK Investigational Site
    • New South Wales
      • Botany, New South Wales, 호주, 2019
        • GSK Investigational Site
      • Coffs Harbour, New South Wales, 호주, 2450
        • GSK Investigational Site
      • Kanwal, New South Wales, 호주, 2259
        • GSK Investigational Site
    • Western Australia
      • Spearwood, Western Australia, 호주, 6163
        • GSK Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.

  2. Asthma for ≥ 6 months, defined as:

    • Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]

    • Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:

      • Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
      • Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
      • Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
      • Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
  3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)

  4. Asthma Control Status

    • Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening

    • Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:

      • Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
      • An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
  5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.

  6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):

    • With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.

    • Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.

      • SABA should be withheld for ≥6 hours
      • Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
  7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:

    • Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.

      • SABA should be withheld for ≥6 hours
      • LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.

Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.

Exclusion Criteria:

  1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
  2. Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
  3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
  4. Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
  5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Salbutamol HFA-152a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 μg (ex-valve) at 30-second intervals per actuation

활성 비교기: Salbutamol HFA-134a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 microgram (μg) (ex-valve) at 30-second intervals per actuation

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Adverse Events (AEs) During Run-in Period
기간: From Week -1 up to randomization (Day 1) during Run-in period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Adverse Events (AEs) During Treatment Period
기간: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
기간: From Week -1 up to randomization (Day 1) during Run-in period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
기간: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Absolute Values of Minimum Serum Potassium
기간: Up to Week 13 (Follow up)

Blood samples were collected to analyze minimum serum potassium.

Up to Week 13 (Follow up)
Absolute Values of Serum Potassium at Each Assessed Visit
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Erythrocytes
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Erythrocytes
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCV
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCH
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hematocrit
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hematocrit
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Specific Gravity
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Specific Gravity
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
기간: Up to Week 13 (Follow up)

Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.

Up to Week 13 (Follow up)
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Vital Signs: Pulse Rate
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Pulse Rate
기간: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
기간: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline for 12 Lead ECGs in QTcF
기간: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Heart Rate
기간: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Heart Rate
기간: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
기간: Baseline (Day 1, pre-dose) and Week 12

The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
기간: Baseline (Day 1, pre-dose) and Week 12

Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: GSK Clinical Trials, GlaxoSmithKline

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 5월 31일

기본 완료 (실제)

2025년 9월 2일

연구 완료 (실제)

2025년 9월 2일

연구 등록 날짜

최초 제출

2024년 2월 8일

QC 기준을 충족하는 최초 제출

2024년 2월 8일

처음 게시됨 (실제)

2024년 2월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 11일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 220735
  • 2023-509001-76-00 (기타 식별자: EU CT Number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 공유 기간

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 공유 액세스 기준

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다